- Home
- JSPR vs PGEN Comparison
JSPR vs PGEN Comparison
Compare JSPR & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- PGEN
- Stock Information
- Founded
- JSPR 2018
- PGEN 1998
- Country
- JSPR United States
- PGEN United States
- Employees
- JSPR N/A
- PGEN N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- PGEN Health Care
- Exchange
- JSPR Nasdaq
- PGEN Nasdaq
- Market Cap
- JSPR 321.8M
- PGEN 292.6M
- IPO Year
- JSPR N/A
- PGEN N/A
- Fundamental
- Price
- JSPR $21.03
- PGEN $0.71
- Analyst Decision
- JSPR Strong Buy
- PGEN Buy
- Analyst Count
- JSPR 11
- PGEN 5
- Target Price
- JSPR $73.38
- PGEN $7.00
- AVG Volume (30 Days)
- JSPR 174.0K
- PGEN 1.0M
- Earning Date
- JSPR 11-07-2024
- PGEN 11-14-2024
- Dividend Yield
- JSPR N/A
- PGEN N/A
- EPS Growth
- JSPR N/A
- PGEN N/A
- EPS
- JSPR N/A
- PGEN N/A
- Revenue
- JSPR N/A
- PGEN $3,963,000.00
- Revenue This Year
- JSPR N/A
- PGEN N/A
- Revenue Next Year
- JSPR N/A
- PGEN $426.76
- P/E Ratio
- JSPR N/A
- PGEN N/A
- Revenue Growth
- JSPR N/A
- PGEN N/A
- 52 Week Low
- JSPR $5.00
- PGEN $0.65
- 52 Week High
- JSPR $31.01
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- JSPR 45.81
- PGEN 38.31
- Support Level
- JSPR $19.41
- PGEN $0.76
- Resistance Level
- JSPR $23.11
- PGEN $0.83
- Average True Range (ATR)
- JSPR 1.83
- PGEN 0.06
- MACD
- JSPR -0.21
- PGEN -0.01
- Stochastic Oscillator
- JSPR 24.40
- PGEN 21.62
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.